Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 59, 2615-2622, June 1, 1999]
© 1999 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adams, J.
Right arrow Articles by Elliott, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adams, J.
Right arrow Articles by Elliott, P. J.
[Cancer Research 59, 2615-2622, June 1, 1999]
© 1999 American Association for Cancer Research


Experimental Therapeutics

Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents

Julian Adams1, Vito J. Palombella, Edward A. Sausville, Jill Johnson, Antonia Destree, Douglas D. Lazarus, Jochen Maas, Christine S. Pien, Samuel Prakash and Peter J. Elliott

ProScript, Inc., Cambridge, Massachusetts 02139 [J. A., V. J. P., A. D., D. D. L., C. S. P., P. J. E.]; Hoechst Marion Roussel, D-60486 Frankfurt am Main, Germany [J. M.]; Hoechst Marion Roussel, Bridgewater, New Jersey 08807 [S. P.]; and Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892 [E. A. S., J. J.]

The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth. Dysregulating the degradation of such proteins should have profound effects on tumor growth and cause cells to undergo apoptosis. To test this hypothesis, we developed a novel series of proteasome inhibitors, exemplified by PS-341, which we describe here. As determined by the National Cancer Institute in vitro screen, PS-341 has substantial cytotoxicity against a broad range of human tumor cells, including prostate cancer cell lines. The PC-3 prostate cell line was, therefore, chosen to further examine the antitumor activity of PS-341. In vitro, PS-341 elicits proteasome inhibition, leading to an increase in the intracellular levels of specific proteins, including the cyclin-dependent kinase inhibitor, p21. Moreover, exposure of such cells to PS-341 caused them to accumulate in the G2-M phase of the cell cycle and subsequently undergo apoptosis, as indicated by nuclear condensation and poly(ADP-ribose) polymerase cleavage. Following weekly i.v. treatment of PS-341 to mice bearing the PC-3 tumor, a significant decrease (60%) in tumor burden was observed in vivo. Direct injection of PS-341 into the tumor also caused a substantial (70%) decrease in tumor volume with 40% of the drug-treated mice having no detectable tumors at the end of the study. Studies also revealed that i.v. administration of PS-341 resulted in a rapid and widespread distribution of PS-341, with highest levels identified in the liver and gastrointestinal tract and lowest levels in the skin and muscle. Modest levels were found in the prostate, whereas there was no apparent penetration of the central nervous system. An assay to follow the biological activity of the PS-341 was established and used to determine temporal drug activity as well as its ability to penetrate tissues. As such, PS-341 was shown to penetrate PC-3 tumors and inhibit intracellular proteasome activity 1.0 h after i.v. dosing. These data illustrate that PS-341 not only reaches its biological target but has a direct effect on its biochemical target, the proteasome. Importantly, the data show that inhibition of this target site by PS-341 results in reduced tumor growth in murine tumor models. Together, the results highlight that the proteasome is a novel biochemical target and that inhibitors such as PS-341 represent a unique class of antitumor agents. PS-341 is currently under clinical evaluation for advanced cancers.




This article has been cited by other articles:


Home page
RadiologyHome page
J. A. Poff, C. T. Allen, B. Traughber, A. Colunga, J. Xie, Z. Chen, B. J. Wood, C. Van Waes, K. C. P. Li, and V. Frenkel
Pulsed High-Intensity Focused Ultrasound Enhances Apoptosis and Growth Inhibition of Squamous Cell Carcinoma Xenografts with Proteasome Inhibitor Bortezomib
Radiology, August 1, 2008; 248(2): 485 - 491.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Z. Chen, J. L. Ricker, P. S. Malhotra, L. Nottingham, L. Bagain, T. L. Lee, N. T. Yeh, and C. Van Waes
Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-{kappa}B and activator protein-1 related mechanisms
Mol. Cancer Ther., July 1, 2008; 7(7): 1949 - 1960.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
A. Shanker, A. D. Brooks, C. A. Tristan, J. W. Wine, P. J. Elliott, H. Yagita, K. Takeda, M. J. Smyth, W. J. Murphy, and T. J. Sayers
Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody
J Natl Cancer Inst, May 7, 2008; 100(9): 649 - 662.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Uddin, M. Ahmed, P. Bavi, R. El-Sayed, N. Al-Sanea, A. AbdulJabbar, L. H. Ashari, S. Alhomoud, F. Al-Dayel, A. R. Hussain, et al.
Bortezomib (Velcade) Induces p27Kip1 Expression through S-Phase Kinase Protein 2 Degradation in Colorectal Cancer
Cancer Res., May 1, 2008; 68(9): 3379 - 3388.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Z. Orlowski and D. J. Kuhn
Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade
Clin. Cancer Res., March 15, 2008; 14(6): 1649 - 1657.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
R. A. Kyle and S. V. Rajkumar
Multiple myeloma
Blood, March 15, 2008; 111(6): 2962 - 2972.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Huang, E. Patterson, X. Yu, M. W. Garrett, I. De Aos, and D. C. Kem
Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1298 - H1303.
[Abstract] [Full Text] [PDF]


Home page
Neuro OncolHome page
C. Yu, B. B. Friday, L. Yang, P. Atadja, D. Wigle, J. Sarkaria, and A. A. Adjei
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells
Neuro-oncol, January 1, 2008; 10(3): 309 - 319.
[Abstract] [Full Text] [PDF]


Home page
PhysiologyHome page
F. Zhang, A. J. Paterson, P. Huang, K. Wang, and J. E. Kudlow
Metabolic Control of Proteasome Function
Physiology, December 1, 2007; 22(6): 373 - 379.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Sartore-Bianchi, F. Gasparri, A. Galvani, L. Nici, J. W. Darnowski, D. Barbone, D. A. Fennell, G. Gaudino, C. Porta, and L. Mutti
Bortezomib Inhibits Nuclear Factor-{kappa}B Dependent Survival and Has Potent In vivo Activity in Mesothelioma
Clin. Cancer Res., October 1, 2007; 13(19): 5942 - 5951.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
C. Naujokat and T. Saric
Concise Review: Role and Function of the Ubiquitin-Proteasome System in Mammalian Stem and Progenitor Cells
Stem Cells, October 1, 2007; 25(10): 2408 - 2418.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Murakawa, E. Sonoda, L. J. Barber, W. Zeng, K. Yokomori, H. Kimura, A. Niimi, A. Lehmann, G. Y. Zhao, H. Hochegger, et al.
Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells
Cancer Res., September 15, 2007; 67(18): 8536 - 8543.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
D. Cilloni, G. Martinelli, F. Messa, M. Baccarani, and G. Saglio
Nuclear factor {kappa}B as a target for new drug development in myeloid malignancies
Haematologica, September 1, 2007; 92(9): 1224 - 1229.
[Abstract] [Full Text] [PDF]


Home page
Eukaryot CellHome page
W. H. Witola and C. Ben Mamoun
Choline Induces Transcriptional Repression and Proteasomal Degradation of the Malarial Phosphoethanolamine Methyltransferase
Eukaryot. Cell, September 1, 2007; 6(9): 1618 - 1624.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C. Peng, J. Brain, Y. Hu, A. Goodrich, L. Kong, D. Grayzel, R. Pak, M. Read, and S. Li
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells
Blood, July 15, 2007; 110(2): 678 - 685.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. D. Demo, C. J. Kirk, M. A. Aujay, T. J. Buchholz, M. Dajee, M. N. Ho, J. Jiang, G. J. Laidig, E. R. Lewis, F. Parlati, et al.
Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the Proteasome
Cancer Res., July 1, 2007; 67(13): 6383 - 6391.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. Shen, W.-Y. Au, T. Guo, K.-Y. Wong, M. L. Wong, J. Tsuchiyama, P.-W. Yuen, Y.-L. Kwong, R. H. Liang, and G. Srivastava
Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation
Blood, July 1, 2007; 110(1): 469 - 470.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Voortman, E. F. Smit, R. Honeywell, B. C. Kuenen, G. J. Peters, H. van de Velde, and G. Giaccone
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
Clin. Cancer Res., June 15, 2007; 13(12): 3642 - 3651.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Kashkar, A. Deggerich, J.-M. Seeger, B. Yazdanpanah, K. Wiegmann, D. Haubert, C. Pongratz, and M. Kronke
NF-{kappa}B-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs
Blood, May 1, 2007; 109(9): 3982 - 3988.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. M. Horton, D. Pati, S. E. Plon, P. A. Thompson, L. R. Bomgaars, P. C. Adamson, A. M. Ingle, J. Wright, A. H. Brockman, M. Paton, et al.
A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study
Clin. Cancer Res., March 1, 2007; 13(5): 1516 - 1522.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J.-P. Armand, A. K. Burnett, J. Drach, J.-L. Harousseau, B. Lowenberg, and J. San Miguel
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib
Oncologist, March 1, 2007; 12(3): 281 - 290.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Dreicer, D. Petrylak, D. Agus, I. Webb, and B. Roth
Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1208 - 1215.
[Abstract] [Full Text] [PDF]


Home page
J Biomol ScreenHome page
F. Ausseil, A. Samson, Y. Aussagues, I. Vandenberghe, L. Creancier, I. Pouny, A. Kruczynski, G. Massiot, and C. Bailly
High-Throughput Bioluminescence Screening of Ubiquitin-Proteasome Pathway Inhibitors from Chemical and Natural Sources
J Biomol Screen, February 1, 2007; 12(1): 106 - 116.
[Abstract] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Gallery, J. L. Blank, Y. Lin, J. A. Gutierrez, J. C. Pulido, D. Rappoli, S. Badola, M. Rolfe, and K. J. MacBeth
The JAMM motif of human deubiquitinase Poh1 is essential for cell viability
Mol. Cancer Ther., January 1, 2007; 6(1): 262 - 268.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A Belch, C. Kouroukis, M Crump, L Sehn, R. Gascoyne, R Klasa, J Powers, J Wright, and E. Eisenhauer
A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150
Ann. Onc., January 1, 2007; 18(1): 116 - 121.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. H. Lang, D. Huber, and R. A. Frost
Burn-induced increase in atrogin-1 and MuRF-1 in skeletal muscle is glucocorticoid independent but downregulated by IGF-I
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R328 - R336.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Papageorgiou, A. Kamat, W. F. Benedict, C. Dinney, and D. J. McConkey
Combination therapy with IFN-{alpha} plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3032 - 3041.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. J. Williamson, J. L. Blank, F. J. Bruzzese, Y. Cao, J. S. Daniels, L. R. Dick, J. Labutti, A. M. Mazzola, A. D. Patil, C. L. Reimer, et al.
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Mol. Cancer Ther., December 1, 2006; 5(12): 3052 - 3061.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
F. Cardoso, V. Durbecq, J.-F. Laes, B. Badran, L. Lagneaux, F. Bex, C. Desmedt, K. Willard-Gallo, J. S. Ross, A. Burny, et al.
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
Mol. Cancer Ther., December 1, 2006; 5(12): 3042 - 3051.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. P. Fanucchi, F. V. Fossella, R. Belt, R. Natale, P. Fidias, D. P. Carbone, R. Govindan, L. E. Raez, F. Robert, M. Ribeiro, et al.
Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 2006; 24(31): 5025 - 5033.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Chen, Q. C. Cui, H. Yang, and Q. P. Dou
Disulfiram, a Clinically Used Anti-Alcoholism Drug and Copper-Binding Agent, Induces Apoptotic Cell Death in Breast Cancer Cultures and Xenografts via Inhibition of the Proteasome Activity
Cancer Res., November 1, 2006; 66(21): 10425 - 10433.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Milacic, D. Chen, L. Ronconi, K. R. Landis-Piwowar, D. Fregona, and Q. P. Dou
A Novel Anticancer Gold(III) Dithiocarbamate Compound Inhibits the Activity of a Purified 20S Proteasome and 26S Proteasome in Human Breast Cancer Cell Cultures and Xenografts
Cancer Res., November 1, 2006; 66(21): 10478 - 10486.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. Aleo, C. J. Henderson, A. Fontanini, B. Solazzo, and C. Brancolini
Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis.
Cancer Res., September 15, 2006; 66(18): 9235 - 9244.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
E. G. Mimnaugh, W. Xu, M. Vos, X. Yuan, and L. Neckers
Endoplasmic Reticulum Vacuolization and Valosin-Containing Protein Relocalization Result from Simultaneous Hsp90 Inhibition by Geldanamycin and Proteasome Inhibition by Velcade
Mol. Cancer Res., September 1, 2006; 4(9): 667 - 681.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. Yu, B. B. Friday, J.-P. Lai, L. Yang, J. Sarkaria, N. E. Kay, C. A. Carter, L. R. Roberts, S. H. Kaufmann, and A. A. Adjei
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Mol. Cancer Ther., September 1, 2006; 5(9): 2378 - 2387.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
C. Brignole, D. Marimpietri, F. Pastorino, B. Nico, D. Di Paolo, M. Cioni, F. Piccardi, M. Cilli, A. Pezzolo, M. V. Corrias, et al.
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
J Natl Cancer Inst, August 16, 2006; 98(16): 1142 - 1157.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Mlynarczuk-Bialy, H. Roeckmann, U. Kuckelkorn, B. Schmidt, S. Umbreen, J. Golab, A. Ludwig, C. Montag, L. Wiebusch, C. Hagemeier, et al.
Combined effect of proteasome and calpain inhibition on Cisplatin-resistant human melanoma cells.
Cancer Res., August 1, 2006; 66(15): 7598 - 7605.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. Leiba, L. Cahalon, A. Shimoni, O. Lider, A. Zanin-Zhorov, I. Hecht, U. Sela, I. Vlodavsky, and A. Nagler
Halofuginone inhibits NF-{kappa}B and p38 MAPK in activated T cells
J. Leukoc. Biol., August 1, 2006; 80(2): 399 - 406.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. E. Canfield, K. Zhu, S. A. Williams, and D. J. McConkey
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
Mol. Cancer Ther., August 1, 2006; 5(8): 2043 - 2050.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Ruiz, Y. Krupnik, M. Keating, J. Chandra, M. Palladino, and D. McConkey
The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.
Mol. Cancer Ther., July 1, 2006; 5(7): 1836 - 1843.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Achanta, A. Modzelewska, L. Feng, S. R. Khan, and P. Huang
A Boronic-Chalcone Derivative Exhibits Potent Anticancer Activity through Inhibition of the Proteasome
Mol. Pharmacol., July 1, 2006; 70(1): 426 - 433.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr, K. P. Lee, and L. H. Boise
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Blood, June 15, 2006; 107(12): 4907 - 4916.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Khan, J. K. Stauffer, R. Williams, J. A. Hixon, R. Salcedo, E. Lincoln, T. C. Back, D. Powell, S. Lockett, A. C. Arnold, et al.
Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors
J. Immunol., May 15, 2006; 176(10): 6302 - 6312.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. J. Strauss, L. Maharaj, S. Hoare, P. W. Johnson, J. A. Radford, S. Vinnecombe, L. Millard, A. Rohatiner, A. Boral, E. Trehu, et al.
Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity
J. Clin. Oncol., May 1, 2006; 24(13): 2105 - 2112.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
C. H. Yang, A. M. Gonzalez-Angulo, J. M. Reuben, D. J. Booser, L. Pusztai, S. Krishnamurthy, D. Esseltine, J. Stec, K. R. Broglio, R. Islam, et al.
Bortezomib (VELCADE(R)) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits
Ann. Onc., May 1, 2006; 17(5): 813 - 817.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. H. Y. Yeung, D.-C. Huang, and F. A. Sinicrope
PS-341 (Bortezomib) Induces Lysosomal Cathepsin B Release and a Caspase-2-dependent Mitochondrial Permeabilization and Apoptosis in Human Pancreatic Cancer Cells
J. Biol. Chem., April 28, 2006; 281(17): 11923 - 11932.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. A. Sausville, A. M. Burger, O. J. Becher, and E. C. Holland
Contributions of human tumor xenografts to anticancer drug development.
Cancer Res., April 1, 2006; 66(7): 3351 - 3354.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Bazzaro, M. K. Lee, A. Zoso, W. L.H. Stirling, A. Santillan, I.-M. Shih, and R. B.S. Roden
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
Cancer Res., April 1, 2006; 66(7): 3754 - 3763.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. T. Nawrocki, J. S. Carew, M. S. Pino, R. A. Highshaw, R. H.I. Andtbacka, K. Dunner Jr., A. Pal, W. G. Bornmann, P. J. Chiao, P. Huang, et al.
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Cancer Res., April 1, 2006; 66(7): 3773 - 3781.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Sors, F. Jean-Louis, C. Pellet, L. Laroche, L. Dubertret, G. Courtois, H. Bachelez, and L. Michel
Down-regulating constitutive activation of the NF-{kappa}B canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis
Blood, March 15, 2006; 107(6): 2354 - 2363.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
B. C. Beehler, P. G. Sleph, L. Benmassaoud, and G. J. Grover
Reduction of skeletal muscle atrophy by a proteasome inhibitor in a rat model of denervation.
Experimental Biology and Medicine, March 1, 2006; 231(3): 335 - 341.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
V. Chung, B. Zhou, X. Liu, L. Zhu, L. M. Boo, H.-V. Nguyen, D. K. Ann, J. Song, Y. Chen, and Y. Yen
SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.
Mol. Cancer Ther., March 1, 2006; 5(3): 533 - 540.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Codony-Servat, M. A. Tapia, M. Bosch, C. Oliva, J. Domingo-Domenech, B. Mellado, M. Rolfe, J. S. Ross, P. Gascon, A. Rovira, et al.
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells.
Mol. Cancer Ther., March 1, 2006; 5(3): 665 - 675.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. T. Efuet and K. Keyomarsi
Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome
Cancer Res., January 15, 2006; 66(2): 1040 - 1051.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Fernandez, T. P. Miller, C. Denoyelle, J. A. Esteban, W.-H. Tang, A. L. Bengston, and M. S. Soengas
Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: IMPACT ON TUMOR CELL DEATH
J. Biol. Chem., January 13, 2006; 281(2): 1107 - 1118.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. M. Roccaro, T. Hideshima, N. Raje, S. Kumar, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Ribatti, B. Nico, A. Vacca, et al.
Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells
Cancer Res., January 1, 2006; 66(1): 184 - 191.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Y. Yamada and G. J. Gorbsky
Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisons
Mol. Cancer Ther., January 1, 2006; 5(1): 29 - 38.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.